The largest group of Black physicians, thought leaders, and celebrities were in one room to have a needed discussion about HIV.

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black women-serving organizations in the U.S. since 2010, with $28 million granted to ...

Despite decades of medical progress, HIV continues to devastate Black communities. The statistics are sobering. The disparities, undeniable.

An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

Why an HIV patient advocacy group is suing the Trump administration over a Biden administration legal settlement with Gilead ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Among its other ratings, Gilead's Accumulation/Distribution Rating of B shows moderate buying by institutional investors over ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

In one late-stage trial, 99.9% of patients who took Gilead's injection did not contract an infection. There were only two cases among more than 2,000 patients, effectively reducing the risk of HIV ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Gilead is prioritizing registering the drug in 18 countries with high HIV incidence rates, including Ethiopia, Kenya, Mozambique, Nigeria, Rwanda, South Africa, Uganda, Zimbabwe, Philippines ...